Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the "Company") a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California. AEZS-130 (Solorel(TM)) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.

Abstract No.851112: "Pharmacological and Toxicological Evaluation of AEZS-130, a Novel, Oral Synthetic Growth Hormone Secretagogue//Ghrelin Receptor Agonist for the Diagnosis of Growth Hormone Deficiency", Babette Aicher, Peter Schmidt, Elena Bresciani, Vittorio Locatelli, Daniel Perrissoud, Michael Teifel Presenter: Dr. Babette Aicher, Associate Director - Screening & Profiling, Preclinical Development, Aeterna Zentaris Date and Time: Sunday, June 20, 2010, 1:30 pm - 3:30 pm (local time) Poster Board No.: P2-340 Location: Halls D-G, San Diego Convention Center